WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SSB 1177

Summary of SSB 1177: Crystalline Polymorph Psilocybin Legislation

Bill Overview

Bill Number: SSB 1177
Title: A bill for an act relating to the controlled substance crystalline polymorph psilocybin
Status: Currently in subcommittee (Klimesh, Rowley, and Wahls)
Introduced On: February 24, 2025
Classification: Proposed bill
Subject Areas: Controlled substances, drugs, felonies, hallucinogenic substances, mushrooms, prescription drugs

Purpose and Intent

The primary purpose of SSB 1177 is to amend the current classification of crystalline polymorph psilocybin, a pharmaceutical composition also known as COMP 360. The bill aims to facilitate the legal prescription, distribution, and marketing of this substance once it receives approval from the United States Food and Drug Administration (FDA).

Key Provisions

  • Removal from Schedule I: The bill proposes that crystalline polymorph psilocybin be removed from Schedule I of the Controlled Substances Act upon its approval by the FDA. This classification currently includes substances deemed to have a high potential for abuse and no accepted medical use.

  • Rescheduling Process: Following FDA approval, the bill mandates that the substance be rescheduled based on FDA recommendations and its listing in the federal Controlled Substances Act (21 U.S.C. §812).

  • Legalization of Prescription and Distribution: Once rescheduled, it will be lawful to prescribe, distribute, and market crystalline polymorph psilocybin under any trade name approved by the FDA.

Impact

  • Healthcare Providers: Medical professionals will be able to prescribe crystalline polymorph psilocybin for therapeutic purposes once it is rescheduled, potentially expanding treatment options for patients.

  • Pharmaceutical Industry: The bill could open new avenues for pharmaceutical companies to develop and market psilocybin-based treatments, contributing to research and innovation in mental health therapies.

  • Regulatory Framework: The bill aligns state law with federal regulations, ensuring that the use of crystalline polymorph psilocybin is governed by established medical guidelines.

Procedural Aspects

  • Legislative Actions:
    • The bill was introduced and referred to the Health and Human Services committee on February 24, 2025.
    • It is currently under consideration by a subcommittee consisting of members Klimesh, Rowley, and Wahls.

Conclusion

SSB 1177 represents a significant shift in the legal status of crystalline polymorph psilocybin, aiming to enhance its availability for medical use while ensuring compliance with federal regulations. If passed, this legislation could have a profound impact on the treatment landscape for mental health conditions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.